NCT07467772 2026-05-22Ph 2 Elacestrant in ER Positive Uterine SarcomasDana-Farber Cancer InstitutePhase 2 Recruiting30 enrolled
NCT07089992 2026-05-14A Study of Pembrolizumab in People With Ultra-Rare SarcomasMemorial Sloan Kettering Cancer CenterPhase 2 Recruiting32 enrolled